Genetic Mechanisms in Interval Colon Cancers

Digestive Diseases and Sciences

Volumn 59, Issue 9, 2014, Pages 2255-2263

  Richter, James M ^a   Pino, Maria Simona ^a,d   Austin, Thomas R ^a   Campbell, Emily ^a   Szymonifka, Jackie ^b   Russo, Andrea L ^c   Hong, Theodore S ^a   Borger, Darrell ^a   Iafrate, A John ^a   Chung, Daniel C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Department of Patient Care Services   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

Colon cancer; Colonoscopy; Lynch syndrome; MSI

Indexed keywords

B RAF KINASE; MISMATCH REPAIR PROTEIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN MLH1;

ADULT; AGED; ARTICLE; ASCENDING COLON; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER SIZE; CANCER STAGING; CECUM; CLINICAL FEATURE; COLON ADENOCARCINOMA; COLON CANCER; COLON DIVERTICULOSIS; COLONOSCOPY; COLORECTAL POLYP; CONTROLLED STUDY; DNA DETERMINATION; DNA METHYLATION; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; INTERVAL COLON CANCER; MALE; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; MISMATCH REPAIR; MUTATION RATE; OCCULT BLOOD; ONCOGENE K RAS; ONCOGENE N RAS; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECTUM; RECTUM HEMORRHAGE; RETROSPECTIVE STUDY; SIGMOID; SOMATIC MUTATION; SPLENIC FLEXURE; TRANSVERSE COLON; TUMOR ASSOCIATED LEUKOCYTE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; ADENOMA; ADENOSINE TRIPHOSPHATASES; ADULT; AGED; AGED, 80 AND OVER; CECAL NEOPLASMS; COLON, ASCENDING; COLONIC NEOPLASMS; COLONIC POLYPS; COLONOSCOPY; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA METHYLATION; DNA MISMATCH REPAIR; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; FEMALE; GENOTYPE; GTP PHOSPHOHYDROLASES; HUMANS; MALE; MEMBRANE PROTEINS; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; TIME FACTORS;

EID: 84907874288     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3134-2     Document Type: Article

References (33)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
2. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544–573.
3. Pignone M, Rich M, Teutsch S, Berg A, Lohr K. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:132–141.
4. Smith R, Cokkinides V, Brawley O. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2009;59:27–41.
5. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale—update based on new evidence. Gastroenterology. 2003;124:544–560.
6. Zauber A, Winawer S, O’Brien M. Significant long term reduction in colorectal cancer mortality with colonoscopic polypectomy: findings of the National Polyp Study. Gastroenterology. 2007;132:A50.
7. Zauber AG, Winawer SJ, O’Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366:687–696.
8. Pohl H, Srivastava A, Bensen SP, et al. Incomplete polyp resection during colonoscopy-results of the complete adenoma resection (CARE) study. Gastroenterology. 2013;144:74–80.
9. Rex DK. Maximizing detection of adenomas and cancers during colonoscopy. Am J Gastroenterol. 2006;101:2866–2877.
10. Jass JR, Stewart SM, Stewart J, Lane MR. Hereditary non-polyposis colorectal cancer—morphologies, genes and mutations. Mutat Res. 1994;310:125–133.
11. Rijcken FEM, Hollema H, Kleibeuker JH. Proximal adenomas in hereditary non-polyposis colorectal cancer are prone to rapid malignant transformation. Gut. 2002;50:382–386.
12. Lindgren G, Liljegren A, Jaramillo E, Rubio C, Lindblom A. Adenoma prevalence and cancer risk in familial non-polyposis colorectal cancer. Gut. 2002;50:228–234.
13. Farris AB III, Demicco EG, Le LP, et al. Clinicopathologic and molecular profiles of microsatellite unstable Barrett Esophagus-associated adenocarcinoma. Am J Surg Pathol. 2011;35:647–655.
14. Dias-Santagata D, Akhavanfard S, David SS, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010;2:146–158.
15. Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res. 2004;10:191–195.
16. Tol J, Nagtegaal ID, Punt CJA. BRAF mutation in metastatic colorectal cancer. N Engl J Med. 2009;361:98–99.
17. Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosom Cancer. 2011;50:307–312.
18. Shen L, Toyota M, Kondo Y, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA. 2007;104:18654–18659.
19. Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009;69:1851–1857.
20. Patel SG, Ahnen DJ. Prevention of interval colorectal cancers: what every clinician needs to know. Clin Gastroenterol Hepatol. 2014;12:7–15.
21. Gonzalez EC, Roetzheim RG, Ferrante JM, Campbell R. Predictors of proximal vs. distal colorectal cancers. Dis Colon Rectum. 2001;44:251–258.
22. Fleshner P, Slater G, Aufses AH Jr. Age and sex distribution of patients with colorectal cancer. Dis Colon Rectum. 1989;32:107–111.
23. Pabby A, Schoen RE, Weissfeld JL, et al. Analysis of colorectal cancer occurrence during surveillance colonoscopy in the dietary Polyp Prevention Trial. Gastrointest Endosc. 2005;61:385–391.
24. Huang Y, Gong W, Su B, Zhi F, Liu S, Jiang B. Risk and cause of interval colorectal cancer after colonoscopic polypectomy. Digestion. 2012;86:148–154.
25. Farrar WD, Sawhney MS, Nelson DB, Lederle FA, Bond JH. Colorectal cancers found after a complete colonoscopy. Clin Gastroenterol Hepatol. 2006;4:1259–1264.
26. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138:2073–2087.
27. Arain MA, Sawhney M, Sheikh S, et al. CIMP status of interval colon cancers: another piece to the puzzle. Am J Gastroenterol. 2010;105:1189–1195.
28. Sawhney MS, Farrar WD, Gudiseva S, et al. Microsatellite instability in interval colon cancers. Gastroenterology. 2006;131:1700–1705.
29. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248–5257.
30. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010;138:2088–2100.
31. Shaukat A, Arain M, Thaygarajan B, Bond JH, Sawhney M. Is BRAF mutation associated with interval colorectal cancers? Dig Dis Sci. 2010;55:2352–2356.
32. Shaukat A, Arain M, Anway R, Manaktala S, Pohlman L, Thyagarajan B. Is KRAS mutation associated with interval colorectal cancers? Dig Dis Sci. 2012;57:913–917.
33. Stoffel EM, Kastrinos F. Familial colorectal cancer, beyond Lynch syndrome. Clin Gastroenterol Hepatol. 2013;13:01195–01196.